Almitrine Bismesylate & Raubasine combines raubasine, a vasodilator; and almitrine, a respiratory stimulant. Raubasine has a adrenolytic activity which is predominantly related to a post-synaptic blocking effect. Furthermore, under conditions of cerebral hypoxia, almitrine causes an increase in the partial pressure of oxygen in arterial blood (Pa02); almitrine causes an increase in the Pa02 and an increase in the oxygen saturation in arterial blood (Sa02), without modifying ventilatory parameters.
Administration:
Not to be used concurrently with other almitrine-containing preparations.
Potentially Fatal: MAOIs.
Adult Dose:
Pregnancy. Long term treatment may result in numbness, prickling or formication effects in the lower limbs which may, in rare cases, lead to treatment withdrawal.
Renal Dose:
Almitrine and raubasine work together to increase the amount of oxygen brought to the brain and neurosensory tissue, by increasing the oxygen content of arterial blood.
Concurrent usage with MAOIs.
This tablet is contraindicated in patients with hypersensitivity to any of the ingredients of it or severe hepatic impairment.
Weight loss, nausea, sensations of heaviness or burning in the stomach, gastrointestinal disorders, diarrhoea or constipation, insomnia, drowsiness, agitation, anxiety, dizziness, palpitations.
Consulting with physicians is required to take this medicine.
Precaution:
Cerebrovascular insufficiency, Functional rehabilitation after cerebrovascular accidents, Auditory, Vestibular and visual disorders of ischaemic aetiology, Stroke
Signs include tachycardia, arterial hypotension, polypnoea and respiratory alkalosis.
Store at a cool and dry place, protected from light and moisture. Keep out of reach of children.
Almitrine Bismesylate & Raubasine combines raubasine, a vasodilator; and almitrine, a respiratory stimulant. Raubasine has a adrenolytic activity which is predominantly related to a post-synaptic blocking effect. Furthermore, under conditions of cerebral hypoxia, almitrine causes an increase in the partial pressure of oxygen in arterial blood (Pa02); almitrine causes an increase in the Pa02 and an increase in the oxygen saturation in arterial blood (Sa02), without modifying ventilatory parameters.
Mild GI disorders, sleep disturbances, palpitations, anxiety, dizziness.
Rarely, wt loss, peripheral neuropathy with abnormal sensations in the lower limbs.
